GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)

Your provider may keep you at a lower dose longer if you are losing steady weight or have issues with side effects: If you need a higher semaglutide dose to continue losing weight, your provider may switch you to Wegovy , which is approved for weight management at doses up to 2.4 mg
Researchers discovered that all three groups showed a significant decrease in weight, BMI, and waist circumference
doi: 10.1186/s12866-016-0759-7 31 KajiharaT.YaharaK.NagiM.KitamuraN.HirabayashiA.HosakaY.et al